He et al. BMC Cancer 2010, 10:681 http://www.biomedcentral.com/1471-2407/10/681 33. Weber WA: Assessing tumor response to therapy. J Nucl Med 2009, 50(Suppl 1):1S-10S. 34. Ollivier L, Thiesse P, Di Stefano D, Vincent C: Measurement of tumour response to cancer treatment: morphologic imaging role. Bull Cancer 2007, 94:171-177. 35. Schuetze SM, Baker LH, Benjamin RS, Canetta R: Selection of response criteria for clinical trials of sarcoma treatment. The Oncologist 2008, 13(Suppl 2):32-40. 36. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van-Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ: Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007, 48:1592-1598. 37. Hoekstra JCorneline, Stroobants GSigrid, Smit FEgbert, Johan Vansteenkiste, van Tinteren Harm, Postmus EPieter, Golding PRichard, Biesma Bonne, Schramel JHMFrans, van Zandwijk Nico, Lammertsma AAdriaan, Hoekstra SOtto: Prognostic relevance of response evaluation using [18F]- 2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:8362-8370. 38. Oremek GM, Sauer-Eppel H, Bruzdziak TH: Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007, 27:1911-1915. 39. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/681/prepub doi:10.1186/1471-2407-10-681 Cite this article as: He et al.: Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. BMC Cancer 2010 10:681. Page 11 of 11 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit